Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03494595
Other study ID # TEG PLT
Secondary ID
Status Recruiting
Phase
First received March 27, 2018
Last updated April 4, 2018
Start date December 2018
Est. completion date February 2023

Study information

Verified date April 2018
Source Assiut University
Contact Ahmed HH Amin
Phone 1060431973
Email ahmed.hamada777@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to correlate the perioperative results of a device called thromboelastogram, which is used to detect coagulation abnormalities, with thrombotic complications during pediatric recipient liver transplantation.


Description:

Pediatric patients undergoing liver transplant are at risk for significant bleeding and thrombotic complications. Studies in both pediatric and adult cohorts estimate an incidence of thrombotic events in up to 26% of cases. Hepatic artery and portal vein thrombosis (PVT) are reported at rates of 5-15% in pediatric cohorts, which is three to four times the incidence in adults. Bleeding estimates are harder to quantify given variability in the definition of major bleeding, but range from approximately 5 to 9%.The contribution of bleeding to morbidity is difficult to quantify, but thrombotic complications are known to reduce graft survival and contribute significantly to adverse outcomes, with mortality rates approaching 50% in those with hepatic artery thrombosis.

Thromboelastometry offers rapid, comprehensive, and global clinical assessment of the patients' coagulation status, as demonstrated by several studies.

Little data exists in the use of thromboelastography (TEG) in pediatric liver transplantation. In 2011, Curiel et al implemented pre-transplant TEGs for patients listed for liver transplantation. The invistigators sought to examine if there were any correlations with preoperative hypercoagulable indices on the TEG and postoperative thrombotic complications.The invistigators have identified that a preoperative hypercoagulable TEG portends to thrombotic complications in pediatric liver transplant patients. Further studies are needed to explore perioperative management strategies for high risk patients to prevent the development of postoperative thrombotic complications based upon preoperative TEG studies. That's why the invistigators will study the perioperative thromboelastometry as a predictor of thrombotic complications during pediatric recipient liver transplantation.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date February 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 3 Months to 15 Years
Eligibility Inclusion Criteria:

- Male or female participant must be between 3 months and 15 years of age.

- Participant is a recipient of a first liver allograft from living donors.

- Participant is a single-organ recipient (liver only).

- Participants' parent/guardian is capable of understanding the purposes and risks of the study and must sign an informed consent for the study.

Exclusion Criteria:

- Pre-existing blood disease.

- A history of liver transplantation.

- Multivisceral transplantation.

- Participants' parent/guardian refused to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Pediatric Liver transplantation
Pediatric Liver transplantation

Locations

Country Name City State
Egypt Assiut university Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intraoperative thrombotic events (hepatic artery or portal vein thrombosis) Any documented thrombus by imaging or clinical diagnosis made by direct observation during a surgical procedure. This includes both venous and arterial thromboembolic events. Intraoperative, an average of 12 hours
Primary Thrombotic events (hepatic artery or portal vein thrombosis) Patients will be screened for hepatic thrombosis regularly with liver Doppler ultrasound during the first week postoperatively, with confirmatory imaging based on identified clinical or imaging concerns. Postoperative up to 1 week.
Secondary Coagulation Time preoperative. Coagulation Time (CT, in seconds), the time from the start of measurement until a clot firmness of 2 mm is detected by thromboelastometry preoperatively. Preoperative up to 1 day before surgery.
Secondary Coagulation Time in pre-anhepatic stage. Coagulation Time (CT, in seconds), the time from the start of measurement until a clot firmness of 2 mm is detected by thromboelastometry during pre-anhepatic stage. In pre-anhepatic stage, an average of 4 hours.
Secondary Coagulation Time in anhepatic stage. Coagulation Time (CT, in seconds), the time from the start of measurement until a clot firmness of 2 mm is detected by thromboelastometry during anhepatic stage. In anhepatic stage, an average of 2 hours.
Secondary Coagulation Time after reperfusion. Coagulation Time (CT, in seconds), the time from the start of measurement until a clot firmness of 2 mm is detected by thromboelastometry after reperfusion. After reperfusion, an average of 4 hours.
Secondary Coagulation Time at the end of surgery. Coagulation Time (CT, in seconds), the time from the start of measurement until a clot firmness of 2 mm is detected by thromboelastometry at the end of surgery. At the end of surgery, an average of 12 hours.
Secondary Clot Formation Time preoperative Clot Formation Time (CFT, in seconds), the time needed to increase clot firmness from 2 to 20 mm amplitude as detected by thromboelastometry preoperatively. Preoperative up to 1 day before surgery.
Secondary Clot Formation Time in pre-anhepatic stage. Clot Formation Time (CFT, in seconds), the time needed to increase clot firmness from 2 to 20 mm amplitude as detected by thromboelastometry during pre-anhepatic stage. In pre-anhepatic stage, an average of 4 hours.
Secondary Clot Formation Time in anhepatic stage. Clot Formation Time (CFT, in seconds), the time needed to increase clot firmness from 2 to 20 mm amplitude as detected by thromboelastometry during anhepatic stage. In anhepatic stage, an average of 2 hours.
Secondary Clot Formation Time after reperfusion. Clot Formation Time (CFT, in seconds), the time needed to increase clot firmness from 2 to 20 mm amplitude as detected by thromboelastometry after reperfusion. After reperfusion, an average of 4 hours.
Secondary Clot Formation Time at the end of surgery Clot Formation Time (CFT, in seconds), the time needed to increase clot firmness from 2 to 20 mm amplitude as detected by thromboelastometry at the end of surgery. At the end of surgery, an average of 12 hours.
Secondary Angle a preoperative. Angle a, the angle of tangent at 2 mm amplitude (ANG a, in degrees) as detected by thromboelastometry preoperatively. Preoperative up to 1 day before surgery.
Secondary Angle a in pre-anhepatic stage. Angle a, the angle of tangent at 2 mm amplitude (ANG a, in degrees) as detected by thromboelastometry during pre-anhepatic stage. In pre-anhepatic stage, an average of 4 hours.
Secondary Angle a in anhepatic stage. Angle a, the angle of tangent at 2 mm amplitude (ANG a, in degrees) as detected by thromboelastometry during anhepatic stage. In anhepatic stage, an average of 2 hours.
Secondary Angle a after reperfusion. Angle a, the angle of tangent at 2 mm amplitude (ANG a, in degrees) as detected by thromboelastometry after reperfusion. After reperfusion, an average of 4 hours.
Secondary Angle a at the end of surgery Angle a, the angle of tangent at 2 mm amplitude (ANG a, in degrees) as detected by thromboelastometry at the end of surgery. At the end of surgery, an average of 12 hours.
Secondary Maximum Clot Firmness preoperative. Maximum Clot Firmness (MCF, in millimeters), the maximum amplitude of clot firmness finally achieved as detected by thromboelastography preoperatively. Preoperative up to 1 day before surgery.
Secondary Maximum Clot Firmness in pre-anhepatic stage. Maximum Clot Firmness (MCF, in millimeters), the maximum amplitude of clot firmness finally achieved as detected by thromboelastography during pre-anhepatic stage. In pre-anhepatic stage, an average of 4 hours.
Secondary Maximum Clot Firmness in anhepatic stage. Maximum Clot Firmness (MCF, in millimeters), the maximum amplitude of clot firmness finally achieved as detected by thromboelastography during anhepatic stage. In anhepatic stage, an average of 2 hours.
Secondary Maximum Clot Firmness after reperfusion. Maximum Clot Firmness (MCF, in millimeters), the maximum amplitude of clot firmness finally achieved as detected by thromboelastography after reperfusion. After reperfusion, an average of 4 hours.
Secondary Maximum Clot Firmness at the end of surgery. Maximum Clot Firmness (MCF, in millimeters), the maximum amplitude of clot firmness finally achieved as detected by thromboelastography at the end of surgery. At the end of surgery, an average of 12 hours.
Secondary Warm ischemic time in minutes during the surgery, an average of 2 hours
Secondary Length of ICU stay in days after the surgery, an average of 1 month
Secondary Length of hospital stay in days postoperative, an average of 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT04518332 - Intraoperative Cerebral and Renal Tissue Oxygen Saturation and Pediatric Living Donor Liver Transplantation Prognosis.
Recruiting NCT04792788 - NAVA vs PSV Ventilation During Weaning From Mechanical Ventilation in Children After Liver Transplantation N/A
Terminated NCT02630563 - Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids Phase 4
Recruiting NCT02957552 - Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation Phase 1
Recruiting NCT02064777 - Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation Phase 4
Not yet recruiting NCT05825703 - Incidence and Risk Factors of Prolonged Post-Operative Mechanical Ventilation